ASSIST — Atrasentan add-on cut proteinuria on RASi + SGLT2i in IgAN (2026) — Trial Summary
ASSIST — Atrasentan add-on cut proteinuria on RASi + SGLT2i in IgAN (2026): Randomized, double-blind, placebo-controlled crossover trial of atrasentan 0.75 mg once daily versus matching placebo in adults with IgA nephropathy, eGFR ≥30 mL/min/1.73 m², and urinary protein >0.5 g/d while on maximal, st
References
- Heerspink HJL, Noronha IL, Górriz JL, et al; ASSIST Investigator Group. Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2026;37(9):2004-2015.